Sabela Recalde

457 total citations
14 papers, 58 citations indexed

About

Sabela Recalde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sabela Recalde has authored 14 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Sabela Recalde's work include Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sabela Recalde is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sabela Recalde collaborates with scholars based in Spain, Australia and Ukraine. Sabela Recalde's co-authors include Ronald P.J. Oude Elferink, María Gión, Lourdes Calvo, Alejandro Martínez‐Bueno, José Manuel Pérez García, Sarai Sarvide, J. Medina, Idoia Morilla, Salvador Blanch and Agostina Stradella and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

Sabela Recalde

14 papers receiving 58 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sabela Recalde Spain 5 41 22 12 10 9 14 58
Alain Gratet France 3 23 0.6× 16 0.7× 9 0.8× 9 0.9× 9 1.0× 7 43
Marc Cucurull Spain 6 79 1.9× 37 1.7× 12 1.0× 6 0.6× 7 0.8× 17 110
Roberto Di Cicilia Italy 5 32 0.8× 22 1.0× 18 1.5× 4 0.4× 5 0.6× 14 63
Tomoyuki Ishiguro Japan 6 102 2.5× 40 1.8× 13 1.1× 4 0.4× 10 1.1× 10 129
Dinesh Kumar Sinha India 4 28 0.7× 15 0.7× 9 0.8× 6 0.6× 18 2.0× 11 57
Yiu-Keung Lau United States 4 29 0.7× 20 0.9× 9 0.8× 4 0.4× 4 0.4× 10 53
B. Valenza France 6 67 1.6× 34 1.5× 31 2.6× 2 0.2× 9 1.0× 10 91
Heinz‐Gert Hoeffkes Germany 5 73 1.8× 41 1.9× 8 0.7× 19 1.9× 7 0.8× 13 82
Dafina Nikolova North Macedonia 4 32 0.8× 14 0.6× 8 0.7× 7 0.7× 9 1.0× 16 51
Francesca Lodi Belgium 4 27 0.7× 10 0.5× 21 1.8× 8 0.8× 13 1.4× 6 74

Countries citing papers authored by Sabela Recalde

Since Specialization
Citations

This map shows the geographic impact of Sabela Recalde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabela Recalde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabela Recalde more than expected).

Fields of papers citing papers by Sabela Recalde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabela Recalde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabela Recalde. The network helps show where Sabela Recalde may publish in the future.

Co-authorship network of co-authors of Sabela Recalde

This figure shows the co-authorship network connecting the top 25 collaborators of Sabela Recalde. A scholar is included among the top collaborators of Sabela Recalde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabela Recalde. Sabela Recalde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Gión, María, Manuel Ruíz‐Borrego, Isabel Blancas, et al.. (2025). Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial. EClinicalMedicine. 85. 103309–103309. 1 indexed citations
2.
3.
García, José Manuel Pérez, María Gión, Manuel Ruíz‐Borrego, et al.. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 1101–1101. 11 indexed citations
4.
Felip, Eudald, Sònia Pernas, Gemma Viñas, et al.. (2024). Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Clinical & Translational Oncology. 26(7). 1748–1758. 2 indexed citations
5.
Stradella, Agostina, Anna Petit, Sabela Recalde, et al.. (2022). Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma. Modern Pathology. 35(8). 1066–1074. 5 indexed citations
6.
Stradella, Agostina, Jenniffer Linares, Sabela Recalde, et al.. (2021). Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. Clinical & Translational Oncology. 23(9). 1761–1768. 4 indexed citations
7.
8.
Stradella, Agostina, Idoia Morilla, Catalina Falo, et al.. (2019). Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. BMC Pharmacology and Toxicology. 20(1). 68–68. 7 indexed citations
9.
Falo, Catalina, Sara Gutiérrez Fernández, Silvia Vázquez, et al.. (2019). Residual cancer burden as a prognostic factor in a large series of neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes. Annals of Oncology. 30. v80–v80. 1 indexed citations
10.
Rodríguez-Freixinós, Víctor, Lorena Fariñas-Madrid, Marta Gil-Martín, et al.. (2018). Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecologic Oncology. 152(2). 270–277. 9 indexed citations
11.
Soler, G., Irune Ruiz, Silvia Vázquez, et al.. (2018). Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool?. Annals of Oncology. 29. viii191–viii191. 1 indexed citations
12.
Soler, G., Cristina Santos, Nuria Mulet, et al.. (2018). Colorectal surgery in the elderly: Does the extreme age determine the odds ratio of complications?. Journal of Clinical Oncology. 36(15_suppl). e22046–e22046. 1 indexed citations
13.
Stradella, Agostina, Sònia Pernas, Noemí Vidal, et al.. (2016). Breast-GPA and type of treatment predictors of survival in brain metastasis patients.. Journal of Clinical Oncology. 34(15_suppl). e13530–e13530. 1 indexed citations
14.
Salas, January T., Jesús M. Bañales, Sarai Sarvide, et al.. (2009). 682 Ae2a,b-DEFICIENT MICE DEVELOP ANTIMITOCHONDRIAL ANTIBODIES AND OTHER FEATURES RESEMBLING PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology. 50. S250–S250. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Gratet Breakdown of academic impact, for papers by Marc Cucurull Breakdown of academic impact, for papers by Roberto Di Cicilia Breakdown of academic impact, for papers by Tomoyuki Ishiguro Breakdown of academic impact, for papers by Dinesh Kumar Sinha Breakdown of academic impact, for papers by Yiu-Keung Lau Breakdown of academic impact, for papers by B. Valenza Breakdown of academic impact, for papers by Heinz‐Gert Hoeffkes Breakdown of academic impact, for papers by Dafina Nikolova Breakdown of academic impact, for papers by Francesca Lodi
Rankless by CCL
2026